Clinical trial
Antineoplaston Therapy in Treating Patients With Primary Liver Cancer
NCT00003530 · Burzynski Research Institute, Other · Terminated
Key facts
| NCT number | NCT00003530 |
|---|---|
| Title | Antineoplaston Therapy in Treating Patients With Primary Liver Cancer |
| Official title | Phase II Study of Antineoplaston A10 in Patients With Primary Liver Cancer |
| Lead sponsor | Burzynski Research Institute, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Liver Cancer |
| Intervention type | Drug |
| Interventions | Antineoplaston therapy (Atengenal + Astugenal) |
| Enrollment | 3 |
| Start date | Mar 21, 1977 |
| Primary completion | Oct 17, 1999 |
| Completion | Oct 17, 1999 |
| First posted | Jan 27, 2003 |
| Last update posted | Nov 21, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: